

August 8, 2017 **BSE Limited** Department of Corporate Services, P. J. Towers, Dalal Street, <u>MUMBAI - 400 001</u>.

National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051.

Dear Sirs,

Sub: Q1 FY18 Investor Presentation.

Pursuant to Regulation 30(2) read with Schedule III Part A (15) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, enclosed is a copy of the Q1-2018 Investor Presentation.

Kindly confirm receipt.

Thanking you,

Yours faithfully, For LUPIN LIMITED

R. V. ŠÄTAM COMPANY SECRETARY

Encl.: a/a

LUPIN LIMITED

LUPIN LIMITED

Q1FY18 Investor Presentation

August 02, 2017



Lupin is a Dominant Force in Global Generics

Globally



Sources:

Bloomberg EQS, 30 Jun 2017
 LTM sales available as of 31 Mar 2017
 QuintilesIMS MAT Mar 17

QuintilesIMS Data Japan (As of Jun 2017) at NHI price basis
 QuintilesIMS MAT Jun 17
 QuintilesIMS MAT Jun 17

Lupin – Awards and Accolades

- Forbes Global 2000, FY 2017
- Lupin ranked No.1 in the Biotech and Pharma, and No. 4 amongst large organisations in the list of top 100 – Great Place to Work
- Dun & Bradstreet Corporate Award in the pharmaceutical sector
- Thomson Reuters India Innovation Award for Research & Development @ Lupin
- Forbes India Business Leadership Awards 2016 Vinita Gupta & Nilesh
 Gupta awarded the Entrepreneur of the Year
- Vinita Gupta in Forbes Asia Power Businesswomen, "Power 50", FY 2016
- Vinita Gupta Hall of Fame The Most Powerful Business Women 2016 by Business Today
- Ramesh Swaminathan: Best CFO Best Inorganic Growth
 Strategy, 2017 by BusinessWorld Best CFO Awards











Our Strategic Direction



2016

- Primarily a Generic
 / Branded Generic
 Business
- 3 strong geographies

2017-2020

- Leading generics player with a larger complex generics mix
- Building Specialty business
- Stronger geographic spread

2020+


- Leading generics player with a significant complex generics mix
- Material Specialty business
- Leading Global player




Particulars (INRmn)	Q1FY18	% of sales	Q1FY17	% of sales	YoY growth	Q4FY17	% of sales	QoQ growth
Net sales	38,068	100.0%	43,418	100.0%	(12.3%)	41,619	100.0%	(8.5%)
Other operating income	628		1,259			914		
Total revenue	38,696		44,677		(13.4%)	42,533		(9.0%)
Gross margin (excl. other operating income)	25,742	67.6%	30,699	70.7%	(16.1%)	29,768	71.5%	(13.5%)
EBITDA	8,003	21.0%	13,934	32.1%	(42.6%)	8,267	19.9%	(3.2%)
EBIT	5,398	14.2%	11,907	27.4%	(54.7%)	5,593	13.4%	(3.5%)
Net profit	3,581	9.4%	8,820	20.3%	(59.4%)	3,802	9.1%	(5.8%)

North America








- US business registered sales of \$238mn
 - Brands grew by 15% to \$23 mn yoy
- 3 product approvals during Q1FY18
- 4 product launches in Q1FY18
- US Market Share: No. 1 in 43 & top 3 in
 - 91 products¹
- 151 pending ANDAs

India






- 6th rank in the IPM¹
- Total field force of 6,680+
- Launched 19 SKUs in Q1FY18
- Therapy-wise split Q1FY18:
 - Chronic sales 57.9%;
 - Semi-chronic sales 27.3%
 - Acute 14.9%
- Lupin had the highest contribution amongst peers from new product introductions in MAT June 2017¹
 - 6 brands are in Top 3 in its therapy¹
 - Gibtulio and Acoglut are in Top 11 amongst Top New Introductions¹
- 85% of portfolio in 12% GST bracket









Japan


- Japan sales grew by 25% y-o-y to JPY 8,585 mn during Q1FY18
- Strengthened CNS positioning with
 - Shionogi brands
 - In-licensing agreement to market Quetiapine Fumarate ER tablets
- 6th largest¹ generic company
- Tottori site commissioned
- Strategic partnership with a national distributor

Philippines

- Philippines sales were PHP 350 mn in Q1FY18
- Ranked 4th branded Gx player²
- Growth of 11.9%² against industry growth of 6.2%²

EMEA






Europe

- Focus on Germany: Sales were €6.7 mn in Q1FY18
- EU 5 markets: Focus on neuro specialty products (viz. Temmler)
 - Expanding EU Partnered Business

 \bullet




- South Africa sales were ZAR 209 mn in Q1FY18
- 4th largest generic company¹ & #1 CVS player¹










Mexico

- Mexico business grew by 13.2% oY to MXN 149 mn during Q1FY18
- IMS growth of 13.5%¹





Brazil

- Brazil business grew by 17.1% y-o-y to BRL 36 mn during Q1FY18
- IMS growth of 30% vs market growth of 9%²










- Enhanced focus on pipeline of complex and first-to-file APIs
- Significant new product portfolio expansion to cater to US/EU/Japan markets
- Foray into Oncology APIs
- Cumulative DMF filings stands at 187 (June 2017)


Manufacturing & R&D– A Diverse Global Network





Our Investments for the Future





R&D Spend

- 151 ANDA pending filings with 1 filing and 3 approvals in Q1FY17 •
- 45 First-to-Files (FTF) filings including 23 exclusive FTF opportunities •
- Enhanced investment on inhalation, biosimilars and injectables